comparemela.com

Latest Breaking News On - Institutional trading of corvus pharmaceuticals - Page 1 : comparemela.com

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Above 50 Day Moving Average of $1.77

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Above 50 Day Moving Average of $1.77
etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.

William-benton-jones
Insider-transactions-at-corvus-pharmaceuticals
Cantor-fitzgerald
Institutional-trading-of-corvus-pharmaceuticals
News-ratings-for-corvus-pharmaceuticals-daily
Nasdaq
Corvus-pharmaceuticals
Corvus-pharmaceuticals-stock
Securities-exchange-commission
Corvus-pharmaceuticals-inc
Vanguard-group-inc
Get-free-report

William Benton Jones Purchases 20,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock

William Benton Jones Purchases 20,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

William-benton-jones
Cantor-fitzgerald
Exchange-commission
News-ratings-for-corvus-pharmaceuticals-daily
Corvus-pharmaceuticals-trading-down
Institutional-trading-of-corvus-pharmaceuticals
Corvus-pharmaceuticals-inc
Nasdaq
Corvus-pharmaceuticals
Securities-exchange-commission
Get-free-report
Pharmaceuticals-trading-down

Corvus Pharmaceuticals, Inc. to Post FY2024 Earnings of ($0.35) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Free Report) – Research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of Corvus Pharmaceuticals in a report issued on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($0.35) per share for the year, up from their prior estimate of […]

News-ratings-for-corvus-pharmaceuticals-daily
Cantor-fitzgerald
Corvus-pharmaceuticals
Corvus-pharmaceuticals-stock-performance
Nasdaq
Tucker-asset-management
Corvus-pharmaceuticals-inc
Acadian-asset-management
Institutional-trading-of-corvus-pharmaceuticals
Free-report
Corvus-pharmaceutical

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Update

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 1,490,000 shares, an increase of 17.3% from the February 29th total of 1,270,000 shares. Based on an average daily trading volume, of 218,100 […]

Corvus-pharmaceuticals-stock-performance
Tucker-asset-management
Corvus-pharmaceuticals-inc
Cantor-fitzgerald
Nasdaq
Renaissance-technologies
News-ratings-for-corvus-pharmaceuticals-daily
Corvus-pharmaceuticals-company-profile
Corvus-pharmaceuticals
Institutional-trading-of-corvus-pharmaceuticals
Tower-research-capital

Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price Passes Above 50-Day Moving Average of $1.43

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $1.43 and traded as high as $1.54. Corvus Pharmaceuticals shares last traded at $1.51, with a volume of 105,012 shares traded. Analyst Ratings Changes A number […]

Nasdaq
Corvus-pharmaceuticals
Charles-schwab-investment-management-inc
Cantor-fitzgerald
Tower-research-capital
Institutional-trading-of-corvus-pharmaceuticals
Corvus-pharmaceuticals-company-profile
York-mellon-corp
Corvus-pharmaceuticals-price-performance
Virtu-financial
Tucker-asset-management

vimarsana © 2020. All Rights Reserved.